KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments

Author： Parsons Barbara L   Myers Meagan B  

Publisher： Future Medicine

ISSN： 1741-0541

Source： Personalized Medicine, Vol.10, Iss.2, 2013-03, pp. : 191-199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond genetics in personalized cancer treatment: assessing dynamics and heterogeneity of tumor responses

By Tyson Darren R   Quaranta Vito  

Personalized Medicine, Vol. 10, Iss. 3, 2013-05 ,pp. : 221-225

Future Medicine

Access to resources Recommend Favorite

Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 2, 2013-06 ,pp. : 93-100

Bentham Science Publishers

Access to resources Recommend Favorite

Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 6, 2015-06 ,pp. : 998-1003

John Wiley & Sons Inc

Access to resources Recommend Favorite

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-07 ,pp. : 503-508

Karger

Access to resources Recommend Favorite

Personalized Network‐Based Treatments in Oncology

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 6, 2013-12 ,pp. : 646-650

John Wiley & Sons Inc

Access to resources Recommend Favorite